Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL
Details
Publication Year 2013-09-19, Volume 122, Issue #12, Page 2093-2103
Journal Title
BLOOD
Publication Type
Journal Article
Abstract
Lmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute lymphoblastic leukemia (T-ALL), including early T-cell precursor ALL (ETP-ALL) cases with poor prognosis. Lmo2 must be recruited to DNA by binding to the hematopoietic basic helix-loop-helix factors Scl/Tal1 or Lyl1. However, it is unknown which of these factors can mediate the leukemic activity of Lmo2. To address this, we have generated Lmo2-transgenic mice lacking either Scl or Lyl1 in the thymus. We show that although Scl is dispensable for Lmo2-driven leukemia, Lyl1 is critical for all oncogenic functions of Lmo2, including upregulation of a stem cell-like gene signature, aberrant self-renewal of thymocytes, and subsequent generation of T-cell leukemia. Lyl1 expression is restricted to preleukemic and leukemic stem cell populations in this model, providing a molecular explanation for the stage-specific expression of the Lmo2-induced gene expression program. Moreover, LMO2 and LYL1 are coexpressed in ETP-ALL patient samples, and LYL1 is required for growth of ETP-ALL cell lines. Thus, the LMO2-LYL1 interaction is a promising therapeutic target for inhibiting self-renewing cancer stem cells in T-ALL, including poor-prognosis ETP-ALL cases.
Publisher
AMER SOC HEMATOLOGY
Keywords
ACUTE LYMPHOBLASTIC-LEUKEMIA; ADULT HEMATOPOIETIC STEM; LIM-PROTEIN LMO2; GENE-THERAPY; CHROMOSOMAL TRANSLOCATIONS; ACTIVATION MECHANISM; FORMS PART; MICE; SCL; TRANSCRIPTION
WEHI Research Division(s)
Cancer And Haematology; Bioinformatics
Rights Notice
© 2013 by The American Society of Hematology


Creation Date: 2013-09-19 12:00:00
Last Modified: 0001-01-01 12:00:00
An error has occurred. This application may no longer respond until reloaded. Reload 🗙